An interventional study of Free gingival graft and Chitosan sponge in Free Gingival Graft Donor Site, sponsored by Biruni University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Biruni University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
An adequate width of keratinized gingiva is important for maintaining periodontal and peri-implant tissue health. Free gingival grafting (FGG) is a commonly performed surgical procedure for increasing insufficient keratinized gingival width. This study aims to evaluate the effect of applying a chitosan sponge to the palatal donor site on wound healing after FGG using exfoliative cytology and to compare the findings with those obtained from a control group in which no chitosan sponge is applied.
At least 40 patients scheduled to undergo FGG because of insufficient keratinized gingival width will be included. The patients will be allocated to two groups: a test group and a control group. In the test group, a chitosan sponge will be applied to the palatal donor site, whereas no wound dressing will be applied to the palatal donor site in the control group. The primary outcome will be the keratinization index determined from cytological samples collected from the palatal donor site at one month after surgery. The keratinization index values at one month will be compared between the test and control groups.
All participants will receive detailed information about the study and the procedures, and written informed consent will be obtained. Clinical measurements will be recorded before surgery, after which the FGG procedure will be performed. Depending on group allocation, the palatal donor site will either be treated with a chitosan sponge or left without a wound dressing. Sutures will be removed on postoperative day 10.
For exfoliative cytological assessment, baseline samples will be collected from both the planned palatal donor site and the contralateral symmetrical healthy palatal site, which will not undergo surgery, in all patients. Samples collected from the symmetrical palatal site will serve as a reference for the baseline characteristics of healthy palatal mucosa. Follow-up samples will be collected exclusively from the palatal donor site on postoperative day 3,10 and at 1, 3, and 6 months. The keratinization index and other cellular features associated with wound healing will be assessed in the cytological samples. Findings obtained during the follow-up periods will be compared between the test group treated with a chitosan sponge and the control group in which no wound dressing is applied. In addition, the presence or absence of sensory loss at the palatal donor site will be evaluated using a periodontal probe.
Biruni University is the lead sponsor of 181 studies on the registry; 46 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Free gingival graft · Other: Chitosan sponge
Procedure: Free gingival graft
Free gingival graft surgery
Suturing of chitosan sponge to the palatal donor site
Palatal donor site tissue thickness:
The thickness of the donor site will be measured using an endodontic reamer.
Time frame: Pre-operative
Palatal donor site tissue thickness:
The thickness of the donor site will be measured using an endodontic reamer.
Time frame: immediate Post-operative
Palatal donor site tissue thickness:
The thickness of the donor site will be measured using an endodontic reamer.
Time frame: day 10
Palatal donor site tissue thickness:
The thickness of the donor site will be measured using an endodontic reamer.
Time frame: day 30
Palatal donor site tissue thickness:
The thickness of the donor site will be measured using an endodontic reamer.
Time frame: day 90
Palatal donor site tissue thickness:
The thickness of the donor site will be measured using an endodontic reamer.
Time frame: day 180
Keratinization Index
Cells without nuclei / Total number of cells examined (n=200) × 100
Time frame: day 3
Keratinization Index
Cells without nuclei / Total number of cells examined (n=200) × 100
Time frame: day 10
Keratinization Index
Cells without nuclei / Total number of cells examined (n=200) × 100
Time frame: day 30
Keratinization Index
Cells without nuclei / Total number of cells examined (n=200) × 100
Time frame: day 90
Keratinization Index
Cells without nuclei / Total number of cells examined (n=200) × 100
Time frame: day 180
Superficial cell index
Total number of cells with and without pyknotic nuclei / Total number of cells examined (n=200) × 100
Time frame: day 3
Superficial cell index
Total number of cells with and without pyknotic nuclei / Total number of cells examined (n=200) × 100
Time frame: day 10
Superficial cell index
Total number of cells with and without pyknotic nuclei / Total number of cells examined (n=200) × 100
Time frame: day 30
Superficial cell index
Total number of cells with and without pyknotic nuclei / Total number of cells examined (n=200) × 100
Time frame: day 90
Superficial cell index
Total number of cells with and without pyknotic nuclei / Total number of cells examined (n=200) × 100
Time frame: day 180
Loss of sensation
To test it objectively, two different movements will be performed with the tip of the probe: immersion and scraping.
Time frame: Day 10
Loss of sensation
To test it objectively, two different movements will be performed with the tip of the probe: immersion and scraping.
Time frame: Day 30
Loss of sensation
To test it objectively, two different movements will be performed with the tip of the probe: immersion and scraping.
Time frame: Day 90
Loss of sensation
To test it objectively, two different movements will be performed with the tip of the probe: immersion and scraping.
Time frame: Day 180
Started Jul 2026 (actual). Primary completion is estimated for Nov 2026, 4 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.